Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
or

Unity Biotechnology Inc (UBX)

Unity Biotechnology Inc (UBX)
0.9760 x 1 0.9839 x 719
Post-market by (Cboe BZX)
0.9800 unch (unch) 04/25/25 [NASDAQ]
0.9760 x 1 0.9839 x 719
Post-market 1.0200 +0.0400 (+4.08%) 16:21 ET
Quote Overview for Fri, Apr 25th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.9800
Day High
1.0400
Open 1.0000
Previous Close 0.9800 0.9800
Volume 88,100 88,100
Avg Vol 139,870 139,870
Stochastic %K 59.54% 59.54%
Weighted Alpha -48.40 -48.40
5-Day Change +0.0070 (+0.72%) +0.0070 (+0.72%)
52-Week Range 0.8531 - 3.1000 0.8531 - 3.1000
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 16,593
  • Shares Outstanding, K 16,868
  • Annual Sales, $ 0 K
  • Annual Income, $ -25,990 K
  • EBIT $ -28 M
  • EBITDA $ -26 M
  • 60-Month Beta 1.30
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.37
  • Most Recent Earnings $-0.43 on 04/22/25
  • Next Earnings Date 05/13/25 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 179.78% ( -63.61%)
  • Historical Volatility 119.45%
  • IV Percentile 55%
  • IV Rank 21.49%
  • IV High 795.52% on 04/15/25
  • IV Low 11.19% on 09/17/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 106
  • Volume Avg (30-Day) 97
  • Put/Call OI Ratio 0.13
  • Today's Open Interest 5,670
  • Open Int (30-Day) 7,828

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.32
  • Number of Estimates 1
  • High Estimate -0.32
  • Low Estimate -0.32
  • Prior Year -0.31
  • Growth Rate Est. (year over year) -3.23%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8531 +14.52%
on 04/08/25
Period Open: 1.2650
1.2700 -23.07%
on 03/26/25
-0.2880 (-22.77%)
since 03/25/25
3-Month
0.8531 +14.52%
on 04/08/25
Period Open: 2.3800
2.4500 -60.12%
on 01/28/25
-1.4030 (-58.95%)
since 01/24/25
52-Week
0.8531 +14.52%
on 04/08/25
Period Open: 1.4800
3.1000 -68.48%
on 01/23/25
-0.5030 (-33.99%)
since 04/25/24

Most Recent Stories

More News
UNITY Biotechnology Announces Publication in NEJM Evidence Highlighting the Potential of Senolytic Therapeutics to Provide Long-Term Improvements in Vision in DME

UBX : 0.9770 (-0.68%)
UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates

UBX : 0.9770 (-0.68%)
UNITY Biotechnology Announces Topline Results from the ASPIRE Phase 2b Study in Diabetic Macular Edema

UBX : 0.9770 (-0.68%)
UNITY Biotechnology to Host Virtual Investor Event to Discuss 24- and 36-Week Data from the Phase 2b ASPIRE Study of UBX1325 in Patients with Diabetic Macular Edema (DME) on March 24, 2025

UBX : 0.9770 (-0.68%)
UNITY Biotechnology Appoints Industry Leader and Ophthalmology Expert Yehia Hashad, M.D., to the Board of Directors

UBX : 0.9770 (-0.68%)
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

UBX : 0.9770 (-0.68%)
UNITY Biotechnology Reports Granting of New Employment Inducement Award

UBX : 0.9770 (-0.68%)
UNITY Biotechnology Announces Appointment of Federico Grossi, M.D., Ph.D., as Chief Medical Officer

UBX : 0.9770 (-0.68%)
UNITY Biotechnology, Inc. Reports Third Quarter 2024 Financial Results and Business Updates

UBX : 0.9770 (-0.68%)
Pre-Market Brief: Stocks Move Higher as Investors Brace for Earnings

December S&P 500 futures (ESZ22) are trending up +0.80% this morning after three major US benchmark indices closed lower on Friday as increasing expectations for higher for longer inflation added to the...

SDIG : 2.81 (+3.31%)
UBX : 0.9770 (-0.68%)
ACOR : 0.6610 (-24.86%)
UNH : 418.64 (-1.32%)
OPEN : 0.7637 (-1.65%)
ESZ22 : 3,871.47s (-0.66%)
Stocks Slip on Weak Chinese Economic Data

Morning Markets September S&P 500 futures (ESU22 ) this morning are down -0.62%. U.S. stock indexes are under pressure today as disappointing economic data from China signals a slowdown in the world’s...

CSCO : 56.71 (+0.75%)
COP : 91.72 (-0.09%)
PTON : 6.29 (+0.16%)
UBX : 0.9770 (-0.68%)
MRO : 28.55 (-1.28%)
ITW : 239.50 (-1.06%)
TOI : 3.31 (+2.48%)
OXY : 40.36 (-0.02%)
HAL : 20.85 (-1.70%)
ESM25 : 5,549.75s (+0.70%)
FANG : 136.76 (+0.44%)
FCX : 37.35 (-0.74%)
UNITY Biotechnology to Present Clinical Data at the American Society of Retina Specialists (ASRS) 40th Annual Scientific Meeting

SOUTH SAN FRANCISCO, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing...

UBX : 0.9770 (-0.68%)
UNITY Biotechnology Reports Granting of New Employment Inducement Award

SOUTH SAN FRANCISCO, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing...

UBX : 0.9770 (-0.68%)
UNITY Biotechnology Announces Appointment of Accomplished Finance and Operations Executive Michael Samar to the Board of Directors

SAN FRANCISCO, May 26, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to...

UBX : 0.9770 (-0.68%)
UNITY Biotechnology, Inc. Reports First Quarter 2022 Financial Results and Business Updates

-Completed enrollment in BEHOLD, the Phase 2 clinical trial of UBX1325 in DME; BEHOLD remains on track with 12-week safety and efficacy data anticipated by...

UBX : 0.9770 (-0.68%)
UNITY Biotechnology Presentations at ARVO 2022 Showcase UBX1325 as an Investigational Novel Therapeutic Modality for Retinal Vascular Diseases

Cellular senescence biology in eye disease was a focal point at ARVO opening symposium...

UBX : 0.9770 (-0.68%)
UNITY Biotechnology Completes Enrollment in BEHOLD, the Phase 2 Study of Senolytic Candidate UBX1325 in Diabetic Macular Edema

12-week safety and efficacy data anticipated by mid-year 2022 24-week safety and efficacy data anticipated before year-end 2022 SOUTH SAN FRANCISCO,...

UBX : 0.9770 (-0.68%)
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates

SOUTH SAN FRANCISCO, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing...

UBX : 0.9770 (-0.68%)
UNITY Biotechnology to Participate in the Cowen 42nd Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing...

UBX : 0.9770 (-0.68%)
UNITY Biotechnology Announces Additional Data from Phase 1 Study of UBX1325 in Advanced Vascular Eye Disease

24-week UBX1325 Phase 1 data presented at Angiogenesis, Exudation, and Degeneration 2022 Conference   Patients with diabetic macular edema (DME) and wet...

UBX : 0.9770 (-0.68%)

Business Summary

UNITY Biotechnology Inc. develops therapeutics which prevents, halts and reverses various diseases. The company's product portfolio includes UBX101, is designed to treat musculoskeletal disease with an initial focus on osteoarthritis. UNITY Biotechnology Inc. is based in California, United States.

See More

Key Turning Points

3rd Resistance Point 1.0833
2nd Resistance Point 1.0617
1st Resistance Point 1.0193
Last Price 0.9770
1st Support Level 0.9553
2nd Support Level 0.9337
3rd Support Level 0.8913

See More

52-Week High 3.1000
Fibonacci 61.8% 2.2417
Fibonacci 50% 1.9765
Fibonacci 38.2% 1.7114
Last Price 0.9770
52-Week Low 0.8531

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective

Info When You Need It Most.

Barchart Premier is one of the most powerful tools in the investment world. Come see why so many subscribers love it — and try it risk-free for 30 days.